StockNews.com Initiates Coverage on Syros Pharmaceuticals (NASDAQ:SYRS)

Analysts at StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report released on Monday. The firm set a “sell” rating on the stock.

SYRS has been the topic of several other research reports. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $3.33.

Syros Pharmaceuticals Trading Up 6.1 %

Shares of SYRS opened at $0.20 on Monday. The stock has a market cap of $5.26 million, a P/E ratio of -0.06 and a beta of 1.29. Syros Pharmaceuticals has a 1 year low of $0.16 and a 1 year high of $7.96. The stock’s 50-day moving average price is $0.21 and its two-hundred day moving average price is $1.28.

Insider Transactions at Syros Pharmaceuticals

In other news, Director Nancy A. Simonian sold 134,713 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the sale, the director now directly owns 41,070 shares in the company, valued at $11,088.90. The trade was a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 12.26% of the stock is owned by insiders.

Institutional Investors Weigh In On Syros Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of SYRS. Two Sigma Securities LLC bought a new position in shares of Syros Pharmaceuticals during the 4th quarter worth approximately $25,000. Exome Asset Management LLC raised its stake in shares of Syros Pharmaceuticals by 87.6% during the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after purchasing an additional 139,400 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of Syros Pharmaceuticals in the 3rd quarter valued at approximately $34,000. Institutional investors and hedge funds own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.